The 100 microgram orally dissolving tablet from Definium Therapeutics beat placebo by 8.1 points on a standard depression scale at six weeks.
A single 100-microgram LSD pill, dissolved on the tongue and taken under supervision but without a therapist-led six-hour session, produced an 8.1-point larger drop on a standard depression scale than placebo at six weeks in a 149-person late-stage trial. The absence of the therapy may be the most important result on the page.
Definium Therapeutics said on Monday that its experimental drug DT120, an orally disintegrating tablet (ODT) formulation of lysergic acid diethylamide (LSD), hit the primary endpoint in the Phase 3 Emerge study in major depressive disorder (MDD). The result is the largest placebo-controlled test of clinical LSD to read out, and the company, formerly known as MindMed until a 2025 rebrand, is now preparing an expedited filing with the US Food and Drug Administration (FDA).
The 100-microgram dose was given once, on day one, with no accompanying psychedelic-therapy protocol. Patients were supervised for safety, but the session length, the integration counseling, and the therapist-driven set-and-setting that defined earlier psychedelic drug development were not part of the regimen.
The topline figures, reported by Definium and confirmed across trade coverage, are straightforward. In 149 patients across 20 US sites, DT120 reduced Montgomery-Åsberg Depression Rating Scale (MADRS) scores by 8.1 points more than placebo at week six, a separation large enough to be clinically meaningful. The lead investigator, John Sonnenberg of Northwestern University Feinberg School of Medicine, called the efficacy "unprecedented" and "potentially practice-changing."
What makes the readout structurally interesting is what is not in the protocol. The psychedelic-medicine model the rest of the field has spent a decade and several billion dollars building, from Compass Pathways' psilocybin paired with therapist preparation and integration sessions to Lykos Therapeutics' MDMA-assisted therapy, assumes a 6-to-8-hour supervised session with a trained psychotherapist in the room. Definium's Emerge trial did not need that apparatus, and the company's plan is to ask the FDA for a label that does not require it.
If the FDA agrees, DT120 enters the market not as a "psychedelic medicine" but as a single-dose depression drug that happens to act on serotonin 2A receptors. The supervised-therapy infrastructure that Compass, Lykos, and a generation of clinic operators have been raising capital to build becomes optional rather than load-bearing. The category's center of gravity shifts from the therapist to the prescription pad.
Several caveats still apply. The 149-patient sample is modest for a Phase 3 in MDD, where trials routinely run into the hundreds. No full dataset has been published, so effect size, durability beyond six weeks, and adverse-event detail are still drawn from a company press release. The trial has no active-comparator arm against selective serotonin reuptake inhibitors (SSRIs), the standard first-line treatment for MDD, so the comparison is to placebo, not to existing antidepressants. Sonnenberg's "practice-changing" framing is his, not a neutral regulatory or methodological read. And FDA approval is being sought, not granted; the label the company eventually receives, particularly on whether a prescriber must be certified or a session must be monitored, will determine whether the format-as-mechanism argument holds in the real world.
The wider context is also unsettled. The psychedelic-medicine field's optimism has been built on a small but consistent signal in psilocybin and MDMA trials and on the assumption that the molecule needs the therapist. Recent LSD work indexed on PubMed suggests the molecule itself is doing more of the work than the field's framing implies. Definium's result, if it holds, is the strongest signal yet that the therapist is the optional layer, not the active ingredient.
For patients with major depressive disorder, the practical question is whether a single supervised dose of a dissolving LSD pill can do what current daily pills often do not. The Phase 3 result says it can beat placebo for at least six weeks. The open question is whether it can beat, or merely complement, what is already in the medicine cabinet, and whether the FDA will let a psychiatrist prescribe it without rebuilding the room around it.